• Precigen released updated long-term follow-up results for PAPZIMEOS in adults with recurrent respiratory papillomatosis, presented at the 2026 ASCO Annual Meeting.
• Most patients who achieved complete responses remained disease-free for years without needing additional procedures or drug treatment, supporting durability in real-world disease management.
• Several patients have stayed in complete response beyond four years, with the median duration not yet reached as follow-up continues.
• The FDA granted PAPZIMEOS seven-year orphan drug market exclusivity, reinforcing its commercial position as the only approved therapy in this adult indication.
• Long-term monitoring has not identified new safety concerns, reducing late-stage risk as the product moves deeper into commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605301430PR_NEWS_USPR_____NY71822) on May 30, 2026, and is solely responsible for the information contained therein.